NCT00377182View on ClinicalTrials.gov

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

PHASE2CompletedINTERVENTIONAL

Enrollment

107

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

Hepatitis C, Chronic

Interventions

DRUG

Copegus

1000/1200mg po daily for 4 weeks

DRUG

PEGASYS

180 micrograms sc weekly for 4 weeks

DRUG

RO5024048 1500mg

1500mg po bid for 4 weeks

DRUG

RO5024048 3000mg

3000mg po bid for 4 weeks

Trial Locations (18)

10029

New York

11030

Manhasset

23249

Richmond

34209

Bradenton

48377

Novi

60637

Chicago

75203

Dallas

80045

Aurora

90822

Long Beach

92154

San Diego

94115

San Francisco

95817

Sacramento

92037-1030

La Jolla

92103-8465

San Diego

32610-0214

Gainesville

27599-7584

Chapel Hill

78234-3879

Fort Sam Houston

00909

Santurce

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00377182 - A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection. | Biotech Hunter | Biotech Hunter